Medicine guide

Thalidomide BMS (previously Thalidomide Celgene)

·

  • Prescription status not stated
  • Cancer treatments and immune-system medicines
Active substance
Thalidomide
Made by
Bristol-Myers Squibb Pharma EEIG

Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.

What it is for

  • Thalidomide BMS in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged >/= 65 years or ineligible for high dose chemotherapy. Thalidomide BMS is prescribed and dispensed according to the Thalidomide Celgene Pregnancy Prevention Programme (see section 4.4).

From the official label · 2026-09-30 · European Medicines Agency

Same active substance, strength and form in other countries

Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.

Medicine passport: one printable page to show a pharmacist abroad

United StatesNo exact match for this strength and form

SpainNo exact match for this strength and form

FranceNo exact match for this strength and form

CanadaNo exact match for this strength and form

NetherlandsNo exact match for this strength and form

Details

Made byBristol-Myers Squibb Pharma EEIG
Active substanceThalidomide
Used inCancer treatments and immune-system medicines
ClassificationL04AX02 · Cancer treatments and immune-system medicines
Authorised on2008-04-16
Last updated by the regulator2025-01-22
EMA product numberEMEA/H/C/000823

Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician

Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).

Same active substance

These contain the same substance. That does not mean one can replace another — ask a pharmacist.